Liquidia Revenue Jumps on Rapid YUTREPIA Launch Despite Wider Loss

Liquidia Corporation reported second-quarter revenue of $8.84 million, a 142% increase from a year earlier, driven by the first shipments of YUTREPIA, its newly approved inhaled formulation of treprostinil for pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease. The North Carolina-based drugmaker posted a net loss of $41.6 million, or $0.49 per share, wider than analysts’ expectation for a $0.42 loss, as selling, general and administrative expenses nearly doubled to support the commercial launch. Demand for YUTREPIA has surged since the U.S. Food and Drug Administration cleared the therapy on 23 May. In the 11 weeks following approval, physicians wrote more than 900 unique prescriptions, leading to over 550 patient starts, according to the company. Liquidia said more than 350 doctors have prescribed the dry-powder treatment, and early uptake occurred ahead of full payer coverage, suggesting additional growth potential in the second half of the year. Liquidia ended the quarter with $173.4 million in cash and is expanding manufacturing capacity with a new 70,000-square-foot facility set to come online in 2026. Management will discuss the results and provide an outlook during a webcast scheduled for 8:30 a.m. Eastern Time on 12 August. The stock rose about 14% in pre-market trading after the release.